Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression.
Overactivation of Wnt-β-catenin signaling, including β-catenin-TCF target gene expression, is a hallmark of colorectal cancer (CRC) development. We identified the immunoglobulin family of cell-adhesion receptors member L1 as a β-catenin-TCF target gene preferentially expressed at the invasive edge of human CRC tissue. L1 can confer enhanced motility and liver metastasis when expressed in CRC cells. This ability of L1-mediated metastasis is exerted by a mechanism involving ezrin and the activation of NF-κB target genes. In this study, we identified the secreted modular calcium-binding matricellular protein-2 (SMOC-2) as a gene activated by L1-ezrin-NF-κB signaling. SMOC-2 is also known as an intestinal stem cell signature gene in mice expressing Lgr5 in cells at the bottom of intestinal crypts. The induction of SMOC-2 expression in L1-expressing CRC cells was necessary for the increase in cell motility, proliferation under stress and liver metastasis conferred by L1. SMOC-2 expression induced a more mesenchymal like phenotype in CRC cells, a decrease in E-cadherin and an increase in Snail by signaling that involves integrin-linked kinase (ILK). SMOC-2 was localized at the bottom of normal human colonic crypts and at increased levels in CRC tissue with preferential expression in invasive areas of the tumor. We found an increase in Lgr5 levels in CRC cells overexpressing L1, p65 or SMOC-2, suggesting that L1-mediated CRC progression involves the acquisition of a stem cell-like phenotype, and that SMOC-2 elevation is necessary for L1-mediated induction of more aggressive/invasive CRC properties.
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
A
A
Shvab
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
G
G
Haase
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
A
A
Ben-Shmuel
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
N
http://orcid.org/0000-0003-1639-4684
N
Gavert
Department of Experimental Medicine 1, University of Erlangen-Nuernberg, Erlangen, Germany.
T
T
Brabletz
Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
S
S
Dedhar
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
A
A
Ben-Ze'ev
D000818:Animals; D002135:Calcium-Binding Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D003110:Colonic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D064593:Heterografts; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D013234:Stem Cells / Q000378:metabolism* / Q000473:pathology; D015533:Transcriptional Activation; D060449:Wnt Signaling Pathway
D002135:Calcium-Binding Proteins; C476827:SMOC2 protein, human